Development of the formulation and technology of bioadhesive buccal tablets with bacteriophages
Introduction. The development of mucoadhesive buccal dosage forms for bacteriophages is a promising strategy to circumvent phage inactivation in the acidic gastric environment and to provide local and systemic antibacterial therapy against infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Aim. To design the formulation and manufacturing technology of bioadhesive buccal tablets loaded with a cocktail of Staphylococcus phages CH1, SCH1, and SCH111, ensuring titer retention, adequate mucoadhesion, and complete release of the active agents. Materials and methods. Phage lyophilizates with sucrose were incorporated into matrices composed of Carbopol® 974 P NF, Benecel K100M, Noveon® AA-1, Metolose™ SM-100, Natrosol® 250G, NEOCEL®-C11, Avicel 102/101, Kollidon 30, and magnesium stearate. Core tablets were produced by direct compression (40 kN) as well as by wet and dry granulation. Mucoadhesion was measured as the detachment force from a mucin-coated substrate using a specially designed apparatus; the pH of the medium after tablet swelling was recorded potentiometrically; phage quantification was performed by the double-agar-layer (Gratia) method; in vitro release was studied in phosphate buffer (pH 6.8) at (37 ± 0.5) °C and 50 rpm; taste was evaluated according to the method of A. I. Tentsova. Results and discussion. Among twenty experimental formulations, composition No. 16 (Carbopol® 15 %, Benecel K100M 15 %) demonstrated the best balance of properties: bioadhesion force (35 ± 2.1) N/cm², disintegration time (147.5 ± 6.4) min, and crushing strength (57 ± 2.9) N. Wet granulation caused a 1—2 log reduction in phage titer, necessitating the adoption of dry granulation. Tablets of composition No. 16 prepared by dry granulation released >85 % of the phages within 45—60 min and generated a neutral pH compatible with the buccal mucosa. Conclusion. The study substantiates the formulation and dry-granulation technology for bioadhesive buccal bacteriophage tablets, which provide titer stability, strong mucoadhesion, and rapid release of the therapeutic phages.
Authors
- S.S. Bochkareva (ORCID: https://orcid.org/0000-0002-1204-7645)
- М. Н. Анурова (ORCID: https://orcid.org/0000-0002-7649-9616)
- Aleksei M. Vorobev (ORCID: https://orcid.org/0000-0003-4724-2464)
- Наталья Борисовна Демина (ORCID: https://orcid.org/0000-0003-4307-8791)
- Andrey V. Aleshkin (ORCID: https://orcid.org/0000-0002-0532-1378)
- Иван Иванович Краснюк (ORCID: https://orcid.org/0000-0002-7242-2988)
- Алексей Кузьмин (ORCID: https://orcid.org/0009-0004-0711-6310)
- A. N. Ivanova (ORCID: https://orcid.org/0009-0003-5400-5288)
Institutions
- Sechenov University (RU)
- Gamalei Institute of Epidemiology and Microbiology (RU)
- Gabrichevsky Institute of Epidemiology and Microbiology (RU)
Publication Details
- Journal
- Drug development & registration
- Published
- 2026-11-20
- DOI
- https://doi.org/10.33380/2305-2066-2026-15-4-2363
- Primary Topic
- Advanced Drug Delivery Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00